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The ﬁrst successful hematopoietic stem cell trans-
plantation (HSCT) in a patient with sickle cell disease (SCD)
was reported in 1984 in a pediatric patient with coexisting
acutemyelogenous leukemia [1] and established the curative
potential of this approach. Myeloablative conditioning with
busulfan and cyclophosphamide followed by human leuko-
cyte antigen (HLA)-matched marrow infusion was later
successfully used in Europe [2,3] and the United States [4] as
primary treatment for severe SCD in children without an
underlying malignancy. Antithymocyte globulin was subse-
quently added to decrease the risk of graft rejection in this
frequently alloimmunized population [4]. Although indica-
tions for transplant have remained controversial in the
pediatric setting, in 1 series patients were divided into 2
groups to reﬂect their access to care: those in Europe with
access to care in whom severity criteria were used and those
in Africa where access to such care is limited. In the second
group the only indication was SCD, and disease severity
criteria were not used. Although overall results were favor-
able, the best results were seen in the second group, sug-
gesting that transplantation before complications are
observed produces better outcomes [5]. The most recent
results reported in 2007 demonstrate that with the addition
of antithymocyte globulin, rejection rates decreased from
22.6% to 3% and event-free survival rates rose to 95.3% among
those undergoing transplantation after January 2000. These
results establish HLA-matched transplants using myeloa-
blative conditioning as the standard of care for eligible
pediatric patients with SCD. Now, hundreds of affected
pediatric subjects have undergone fully myeloablative allo-
geneic HSCT with favorable results.
Although these results in children are encouraging,
procedural toxicities that increase with advancing age have
limited this approach to pediatric patients. The ability to
achieve engraftment of allogeneic HSCs without myleoa-
blative conditioning prompted many to consider this
strategy in nonmalignant disorders as increased safety was
assumed, potentially allowing application to older patients
and patients with comorbidities. In many such studies,
prompt myeloid engraftment was observed in all yet
appeared to result from a donor Tcellemediated alloimmune
response that was associated with signiﬁcant rates of graft-Financial disclosure: See Acknowledgments on page S9.
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mortality [6]. Furthermore, early studies attempting non-
myeloablative transplantation in SCD proved unsuccessful
[7]. Others began to explore reduced-intensity conditioning,
which often contained agents that were ablative at near
ablative doses, with improved success [8]. Based on rapa-
mycin’s ability to promote T cell tolerance even when T cells
are stimulated in the presence of costimulation [9] both
in vitro and in vivo [10], a clinical trial testing this approach
was initiated in severely affected adults. The primary
endpoint of the study was the proportion of patients with
stable engraftment, with the incidence of GVHD as
a secondary endpoint. HLA-identical relatives underwent
granulocyte colony-stimulating factor mobilization, and
these unmanipulated HSCs were infused after conditioning
with alemtuzumab 1 mg/kg total, given over 5 days; a single
dose of 300 cGy total body irradiation; and oral sirolimus
(rapamycin) initiated on daye1. Stablemixed chimerism and
disease reversion was observed in 9 of the ﬁrst 10 patients
treated [11]. Additionally, no GVHD was observed among
engrafted patients. Expansion of the cohort to now 25
patients has resulted in similar rates of engraftment, with 22
of 25 patients disease-free again in the absence of GVHD.
These data support mixed chimerism as a suitable goal for
HSC transplantation in SCD.
The success of this regimen provides indirect evidence for
graft-speciﬁc tolerance, opening the possibility of expanding
to alternative donor sources. Indeed, the main limitation has
been a lack of HLA-matched sibling donors in most patients
with SCD. To determine availability of alternative donor
sources, 10 patients who met all study criteria on full
screening for sibling-matched HSCT but who did not have
a suitable donor were selected for alternative donor
searching in the National Marrow Donor Program and Bone
Marrow Donors Worldwide. Whereas 7 of 10 had a potential
6/6 matched unrelated donor, only 1 of 7 had a greater than
1% probability of having a 6/6 HLA match according to
Haplogic. When cord blood units were searched, 9 of 10 had
at least one 4/6 cord blood match identiﬁed (1.5  107 total
nucleated cells/kg body weight and ABO matched). When
higher degrees of matching (5/6) and higher cell doses were
queried (2.5  107 total nucleated cells/kg body weight and
ABO matched), only 2 patients had a suitable cord product
(Hsieh, M. 2012; personal communication).
Thus, nonmyeloablative haploidentical HSCT strategies
are currently being explored because they appear to be
the only current reliably obtainable stem cell source.
Although extension of the low-dose total body irradi-
ationeCampatherapamycin approach may be feasible in the
haploidentical setting, additional methods aimed at reducing
the risk of both rejection and GVHD will likely be required.Transplantation. Published by Elsevier Inc. All rights reserved.
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transplantation has been shown to facilitate engraftment
and prevent the development of GVHD by targeting activated
lymphocytes. Recently, 14 individuals with SCDwho received
nonmyeloablative haploidentical bone marrow trans-
plantation using postgraft cyclophosphamide were reported,
with engraftment in about half of the subjects. Although
higher rates of engraftment are desirable, these results are
encouraging because they were achieved in the absence of
signiﬁcant GVHD and no mortality was seen [12]. Addition-
ally, a haploidentical protocol using total body irradi-
ationeCampatherapamycin has also recently opened to
accrual at the National Institutes of Health. The study is
designed as a dose escalation study testing postgraft cyclo-
phosphamide and accrual is ongoing.
In summary, HSCT for patients with SCD is highly effec-
tive, reversing the phenotype even when low levels of donor
engraftment are achieved with newer, less toxic regimens.
Results in children with myeloablative conditioning in the
current era suggest that this therapy is underutilized. Future
well-designed studies testing nonmyeloablative condi-
tioning regimens and alternative donor sources are poised to
expand the application of the approach and lead the ﬁeld in
immune tolerance. Continued efforts to develop allogeneic
transplantation for SCD, with the goal of maximizing
engraftment rates while minimizing morbidity and
mortality, are indeed justiﬁed.
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CHOICE OF ALTERNATIVE DONORS FOR APLASTIC ANEMIA
Mary Eapen
Treatments for aplastic anemia include immune
suppressive therapy (IST) with antithymocyte globulin
(ATG), which lyses lymphocytes; cyclosporine, which blocks
T lymphocyte function; and hematopoietic stem celltransplantation (HSCT), which replaces all hematopoietic
progenitor cells, including lymphopoietic cells [1]. There is
general agreement that, when a human leukocyte antigen
(HLA)-matched sibling is available, HSCT is ﬁrst-line treat-
ment for most patients with severe aplastic anemia (SAA).
Conversely, IST is used as ﬁrst-line therapy for patients who
do not have an HLA-matched sibling and must seek an
alternative donor [2]. Whether alternative donor HSCT
should be performed after failing one or more than one
course of IST is uncertain and depends, in part, on patient
factors predicting the likelihood of further response to IST
and the likelihood of good outcome with HSCT, as well as
timely availability of a suitable donor.
Unrelated Adult Donor Transplantation
Unrelated donor transplantation is an effective therapy
for SAA but is limited by the availability of a suitablymatched
unrelated donor and is associated with higher risks of graft
failure, graft-versus-host disease, and mortality than HLA-
matched sibling transplantation. Selecting an appropriately
matched donor for HSCT is an important component of
success. Several groups have attempted to compare
outcomes of transplantation for aplastic anemia using 8/8
HLA-matched versus HLA-mismatched grafts. Among 118
children and adolescents with aplastic anemia undergoing
transplantation between 1989 and 2003 with unrelated
adult donor bone marrow grafts, mortality risks were lower
after HLA-matched versus mismatched transplants [3]. Ten-
year probabilities of overall survival were 57% after 8/8
HLA-matched transplants compared with 39% after 7/8
HLA-matched transplants [3]. In another report, survival
probabilities after 8/8 HLA-matched unrelated donor bone
marrow transplantation was higher at 75% [4]. In that report
lower survival rates were 61% after peripheral blood stem
cell transplantation. These observations support bone
marrow as the preferred graft when considering unrelated
donor transplantation. Importantly, advances in trans-
plantation strategies including selection of better-matched
donors have resulted in substantial improvements in
survival after unrelated donor transplantation (32% before
1998, 61% before 2005, and now 75%).
In the absence of a suitably matched adult unrelated
donor, umbilical cord blood (UCB) has been used as an
alternative graft. Data from Eurocord and the Japan Cord
Blood Bank Network suggest survival probabilities of about
40%. In addition to HLA disparity and the less than optimal
cell dose in UCB grafts, it is likely that in some cases the
reason for inferior survival is because these transplantations
are often done for patients who have failed multiple courses
of IST. To date there are no direct comparisons of outcomes
after a second (or third) course of IST and unrelated donor
transplantations.
Transplantation Strategies: Conditioning Regimen
Alternative donor transplants have higher rates of graft
failure, regimen-related toxicity, and graft-versus-host
disease than HLA-matched sibling transplants, even when
the donor and recipient are 8/8 HLA matched. Unrelated
donor transplantations performed in the 1980s and 1990s
incorporated high doses of total body irradiation (TBI) to
prevent graft failure. However, high-dose TBI regimens are
associated with severe acute toxicity and secondary
malignancies. Therefore, to lower early toxicity and
secondary malignancy, recent transplant conditioning
regimens have used lower doses of TBI in combination with
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identiﬁed 200 cGy of TBI administered as a single dose
together with cyclophosphamide (200 mg/kg) and equine
ATG (90 mg/kg) as the optimal regimen in a radiation dose
de-escalation study; graft failure occurred in 5% of patients
and 5-year survival was 55%. Regimen-related toxicity
(grade 3 or higher) and death decreased with de-escalation
of the TBI dose. Age was an important predictor of survival;
the 5-year probability of overall survival in younger
patients (20 years) was 73% compared with 46% in older
patients (P ¼ .05). Lowering the dose of TBI had no effect on
graft failure. Further attempts at de-escalating the dose of
cyclophosphamide yielded mixed results. A recent report
from an ongoing clinical trial in the United States showed
excess mortality in the TBI (200 cGy), cyclophosphamide
150 mg/kg, ﬂudarabine 120 mg/m2, ATG 9 mg/kg, or
ATGAM 90 mg/kg regimen and excess graft failure when
cyclophosphamide was eliminated from the regimen [6].
Accrual to the cyclophosphamide 100 mg/kg and 50 mg/kg
regimen continue, and the trial is expected to complete
accrual early in 2013.
Conclusion
The selection of more closely HLA-matched unrelated
donors and lowering the intensity of transplant conditioning
regimens have had a signiﬁcant effect on survival after
transplantation for SAA. Bone marrow is the preferred graft
source. The role of UCB transplantation in patients without
an HLA-matched adult donor needs further exploration.
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HEMATOPOIETIC CELL TRANSPLANTATION FOR SEVERE
MULTIPLE SCLEROSIS
Riccardo Saccardi
Multiple sclerosis (MS) is a chronic inﬂammatory
demyelinating disease believed to be mediated by autor-
eactive lymphocytes that invade the central nervous system
and cause oligodendrocyte, axonal and neuronal damage as
well as glial scarring, resulting in demyelination, neuronal
death and brain atrophy. In most patients, the onset of the
disease is characterized by recurrent attacks, with or
without complete recovery, resulting in an accumulation of
disability, intermediated by clinical remissions (relapsing-
remitting [RR] phase). This phase is pathologically charac-
terized by focal perivenular inﬁltrates dominated by T and
monocytoid cells. After years to decades, the inﬂammatory
component gradually becomes more diffuse, the attacks
become less apparent and more often disappear, anddisability tends to slowly progress (secondary-progressive
[SP] phase). During this phase the continuous clinical
deterioration is mainly sustained by degenerative changes,
including axonal and neuronal loss and a more diffuse
microglial inﬁltration [1].
Neurological monitoring is conducted through both
clinical and magnetic resonance imaging (MRI) parameters.
A number of indexes have been developed to assess the
clinical disability according to different performance scores;
the most popular is the Kurtzke Expanded Disability Status
Scale (EDSS), ranging from 0 (normal neurological exami-
nation) to 10 (MS-related death). Progression of the disability
is deﬁned as an increase of the EDSS score, conﬁrmed after 3
to 6 months. MRI has become the most important diagnostic
tool in MS, and for a number of years the diagnosis of MS is
largely based on MRI alterations that show brain lesions
disseminated in space. Conventional MRI metrics include
gadolinium-enhancing lesions (Gdþ), a measure of bloode
brain barrier disruption associated with acute inﬂammatory
lesions; and T2 lesions, a sensitive measure of demyelinating
lesions. Loss of brain tissue or atrophy is determined by
measuring decreased brain volume.
Available treatments for MS include high-dose steroids
for the treatment of acute phases and immunomodulatory/
immunosuppressive drugs chronically administered to
reduce the number of relapses, decrease their severity, and
slow down the progression of disability. However, no
disease-modifying agent has been shown to modify long-
term outcome; moreover, a subset of patients shows an
aggressive clinical pattern at the onset associatedwith a poor
response to conventional treatments. It is particularly this
group of patients (ie, those failing multiple treatments and
accumulating clinical disability rapidly) for which treatment
alternatives are needed.
Autologous hematopoietic stem cell transplantation
(HSCT) has been experimented with over the last 15 years in
the treatment of severe autoimmune diseases that progress
despite the administration of standard treatments. The
rationale is derived both from experimental models and from
the observations of positive effects of transplants for
conventional indications and a coincidental autoimmune
disease. Autologous HSCT for MS has been used since 1997
[2,3] and currently, approximately 1000 patients have been
treated worldwide, who are in the registry of either the
European Group for Blood and Marrow Transplantation
(EBMT, www.ebmt.org) or the Center for International Blood
and Marrow Transplant Research (CIBMTR, www.cibmtr.
org). This HSCT procedure results in a profound renewal of
the immune system [4] and in a drop of inﬂammatory
activity, as assessed by MRI [5]. Most patients were included
in small, either single-center or multicenter, phase I to II
trials, and no data are currently available from prospective
comparative trials. A major clinical response was reported in
most of the published studies, the neurological outcome
being particularly favorable in patients transplanted in the
RR phase and/or showing an inﬂammatory pattern at MRI
during the pre-transplantation screening. Case series and
reports about the excellent outcome in particularly aggres-
sive forms of MS support the efﬁcacy of HSCT in MS patients
with prominent inﬂammatory activity. In particular, a sus-
tained EDSS improvement was reported more frequently in
RR patients over SP patients [6].
Peripheral blood stem cells are usually well mobilized
in MS patients; mobilization with the administration
of granulocyte colony-stimulating factor and without
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incidence of disease recurrences and must be prevented by
the administration of steroids. High-intensity conditioning
regimens, including either busulfan or total body irradiation,
were not shown to result in a more efﬁcient control of the
disease [7]. Reduced-intensity regimens (cyclophosphamide
and antithymocyte globulin) showed a low transplant-
related toxicity but a higher incidence of relapses [8].
BEAM (BCNU, etoposide, ara-C, melphalan) plus antithymo-
cyte globulin is the most frequent regimen reported to the
EBMT Registry, showing a satisfactory equipoise of toxicity
and efﬁcacy [9]. Transplant-related mortality dropped from
7.3% from 1995 to 2000 to 1.3% from 2001 to 2007, probably
due to a better patient selection and the use of less-intense
conditioning regimens.
Indications for HSCT in MS have been recently reviewed
by the EBMT [9] in light of the clinical outcomes reported in
the literature. The ideal target patient for autologous HSCT is
one who is in the RR phase and shows high inﬂammatory
activity, both clinically and with an MRI. SP patients should
only be considered when some inﬂammatory activity is still
present, either clinically (evidence of relapses in the previous
year) or by MRI (accumulation of lesion in T2 scans in the
previous year), therefore representing the transition phase
between RR and SP, respectively.
Data reported in prospective phase I and II studies show
that an 80% to 90% progression-free survival at 3 years from
HSCT is expected in RR patients, whereas it drops to 50% in SP
forms. An EBMT retrospective analysis on 143 MS patients
showed that 63% of patients, mostly transplanted in the SP
phase, were stable or improved at a median of 41.7 months
after HSCT [10]. However, MS is a chronic, progressive
disease and assessment of long-term outcome is needed to
provide realistic evidence of efﬁcacy of any treatment. A joint
EBMTeCIBMTR retrospective study, collecting data frompatients with a follow-up ranging between 4 and 12 years, is
currently ongoing. A prospective, comparative trial is also in
preparation [11].
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